Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)
Johnson & Johnson's (JNJ) quarterly Income from Non-Controlling Interests came in at -$339.0 million in Q3 2012.
Analysis
Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends
Johnson & Johnson has disclosed Income from Non-Controlling Interests across 1 years of filings, most recently posting -$339.0 million for Q3 2012.
- In Q3 2012, Income from Non-Controlling Interests changed N/A year-over-year to -$339.0 million; the TTM figure through Dec 2013 stood at -$339.0 million (changed N/A YoY), while the FY2012 annual figure was -$339.0 million, changed N/A from the prior year.
- Income from Non-Controlling Interests came in at -$339.0 million for Q3 2012 at Johnson & Johnson.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$339.0 million in Q3 2012 to a low of -$339.0 million in Q3 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -1.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 39.52 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |